

Pharmacy Name: Address: City/State/Zip: Phone: Fax: Email:

		Gastroenterol	ogy Referro	al Form	1			
		**Please Attach Copy of I						
Last Name: First Name:			DOB:	DOB: Practice:				
Address:					Address:			
City:	State	: Zip:	Sex:	M F	City:	State:	Zip:	
Phone:		SSN#			Prescriber Nan	ne:		
	Insuran	ce Information			Prescriber NPI:	:		
Insurance Plan:				Nurse/Key Contact:				
Policy #				Phone:				
Plan I.D. #		Plan I.D. #	Plan I.D. #			Fax: Email:		
		Diagnosis & Cl	inical Infor	matior)			
Crohn's Dise Ulcerative C Other: Currently receive Length of treatm	TB/PPD Test: Positive Negative Date: Allergies: NKDA Height: Weight: AIC Other:							
Reason for disco	ontinuation				AIC	Other:		
		Prescriptio	n Information					
Medication	Dose/Strength		Directio	ns				Refills
Entyvio (vedolizumab)	300mg vial	INITIAL: Infuse 300mg IV at week 0, 2, 6, then every 8 weeks thereafter MAINTENANCE: Infuse 300mg IV every weeks						
Inflectra Remicade BRAND NAME ONLY SUBSTITUTION ALLOWED Renflexis Avsola	100mg vial	INITIAL: Infuse mg/kg IV at week 0, 2, 6, then every 8 weeks thereafter MAINTENANCE: Infuse mg/kg IV every weeks Other Pharmacist will round to the nearest 100mg Give exact dose (do NOT round)						
Stelara (ustekinumab)	130mg / 26mL vial	INITIAL: Weight based dosing, infuse IV 55kg or less: 260mg (2 vials) Greater than 85kg: 520 mg (4 vials) MAINTENANCE: Inject 90mg SC 8 weeks after initial dose, then every 8 weeks thereafter						
Skyrizi (risankizumab)	600mg / 10mL vial 180mg / 1.2mL 360mg / 2.4mL	INITIAL: Infuse 600mg/10mL IV at week 0, 4, and 8 MAINTENTANCE: 180mg or 360mg by SC injection at week 12, then every 8 weeks thereafter						
Other								
* Infusion supp	Acetaminophen Diphenhydramine 250mL 0.9%NaCl for hyd Other	mg PO prior to infusion mg PO IV * NaCl 0.9% 10mL * Before and after infusion						
Avsola Pharmacist will round to the nearest 100mg Give exact dose (do NOT round) Stelara (ustekinumab) 130mg / 26mL vial (ustekinumab) 55kg or less: 260mg (2 vials) 55kg to 85kg: 390mg (3 vials) Greater than 85kg: 520 mg (4 vials) MAINTENANCE: Inject 90mg SC 8 weeks after initial dose, then every 8 weeks thereafter Skyrizi (risankizumab) 180mg / 1.2mL 360mg / 2.4mL MAINTENANCE: 180mg or 360mg by SC injection at week 12, then every 8 weeks thereafter Other							eafter	

Not a valid prescription in Arizona

PRESCRIBER MUST MANUALLY SIGN STAMP SIGNATURE' SIGNATURE BY OTHER PERSONNEL AND COMPUTER GENERATED SIGNATURES WILL NOT BE ACCEPTED

The attached document(s) contain confidential information which may be considered to be Protected Health Information and therefore required to be maintained as private and secure under HIPAA. The documents may also contain information which is otherwise considered to be privileged under state and federal laws. This communication is for the intended recipient only. If you are not the intended recipient, or a person responsible for delivering this communication to the intended recipient, vor use most copying and/or distributing the information contained herein. Unlawful disclosure of the information attached may subject you to monetary penalties and sanctions. If you have received this communication in error, you should notify the sender immediately and thereafter permanently destroy all copies of this document in its entirety.